Malaria vaccine: why is it taking so long?

References

• Snowden F. The Conquest of Malaria: Italy, 1900–1962. Yale University Press, CT, USA (2006).
   Google Scholar
• Herrington DA, Clyde DF, Losansky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature328, 257–259 (1987).
   PubMed Web of Science ®Google Scholar
• Ballou WR, Hoffman SL, Sherwood JA et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet1, 1277–1281 (1987).
   PubMed Web of Science ®Google Scholar
• Valero MV, Amador LR, Galindo C et al. Vaccination with Spf 66 a chemically synthesized vaccine, against Plasmodium falciparum malaria in Colombia. Lancet341, 705–710 (1993).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Smith T, Armstrong Schellenberg JQM et al. Randomised trial of efficacy of Spf 66 vaccine against Plasmodium falciparum malaria in children in South Tanzania. Lancet344, 1175–1181 (1994).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner D et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J Med.336, 86–91 (1997).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366, 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet370, 1543–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Sherman IW. The Elusive Malaria Vaccine: Miracle or Mirage. ASM Press, Washington, DC, USA (2009).
   Google Scholar
• Gardner MJ, Hall N, Fung E, White O et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature419, 498–511 (2002).
   PubMed Web of Science ®Google Scholar
• Aguiar JC, LaBaer J, Blair PL. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res.14, 2076–2082 (2004).
   PubMed Web of Science ®Google Scholar
• Mehlin C, Boni E, Buckner FS. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol. Biochem. Parasitol.148, 144–160 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuboi T, Takeo S, Iriko H et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun.76, 1702–1708 (2008).
   PubMed Web of Science ®Google Scholar
• Corradin G, Villard V, Kajava AV. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr. Metab. Immune Disord. Drug. Targets7, 259–265 (2007).
   PubMedGoogle Scholar
• Villard V, Agak GW, Frank G et al. Rapid identification of malaria vaccine candidates based on a-helical coiled coil protein motif. PLoS One2, e645 (2007).
   PubMed Web of Science ®Google Scholar
• Barlow Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature322, 747–748 (1986).
   PubMedGoogle Scholar
• Martin L, Vita C. Engineering novel bioactive mini-proteins from small size natural and de novo designed scaffolds. Curr. Protein Pept. Sci.1, 403–430 (2000).
   PubMed Web of Science ®Google Scholar
• Lu SM, Hodges RS. A de novo designed template for generating conformation-specific antibodies that recognize a-helices in proteins. J. Biol. Chem.277, 23515–23524 (2002).
   PubMedGoogle Scholar
• Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science262, 1401–1407 (1993).
   PubMed Web of Science ®Google Scholar
• Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol.293, 321–331 (1999).
   PubMed Web of Science ®Google Scholar
• Feng ZP, X. Zhang X, Han P, Arora N, Anders RF, Norton RS. Abundance of intrinsically unstructured proteins in P. falciparum and other apicomplexan parasite proteomes. Mol. Biochem. Parasitol.150, 256–267 (2006).
   PubMed Web of Science ®Google Scholar
• Olugbile S, Kulangara C, Bang G et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated P. falciparum protein PFF0165c. Infect. Immun.77, 5701–5709 (2009).
   PubMed Web of Science ®Google Scholar
• Kulangara C, Kajava AV. Corradin G, Felger I. Sequence conservation in Plasmodium falciparum α-helical coiled coil domains proposed for vaccine development. PLoS One4, e5419 (2009).
   Google Scholar